| Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors S Iivanainen, J Ahvonen, A Knuuttila, S Tiainen, JP Koivunen Esmo Open 4 (4), e000531, 2019 | 67 | 2019 |
| ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study S Iivanainen, T Alanko, K Peltola, T Konkola, J Ekström, H Virtanen, ... Journal of Cancer Research and Clinical Oncology 145, 765-774, 2019 | 46 | 2019 |
| Digital monitoring and management of patients with advanced or metastatic non-small cell lung cancer treated with cancer immunotherapy and its impact on quality of clinical … O Schmalz, C Jacob, J Ammann, B Liss, S Iivanainen, M Kammermann, ... Journal of Medical Internet Research 22 (12), e18655, 2020 | 31 | 2020 |
| Early PD-1 therapy discontinuation in responding metastatic cancer patients S Iivanainen, JP Koivunen Oncology 96 (3), 125-131, 2019 | 26 | 2019 |
| Follow-up of cancer patients receiving anti-PD-(L) 1 therapy using an electronic patient-reported outcomes tool (KISS): Prospective feasibility cohort study S Iivanainen, T Alanko, P Vihinen, T Konkola, J Ekstrom, H Virtanen, ... JMIR Formative Research 4 (10), e17898, 2020 | 25 | 2020 |
| Possibilities of improving the clinical value of immune checkpoint inhibitor therapies in cancer care by optimizing patient selection S Iivanainen, JP Koivunen International Journal of Molecular Sciences 21 (2), 556, 2020 | 25 | 2020 |
| Electronic patient-reported outcomes and machine learning in predicting immune-related adverse events of immune checkpoint inhibitor therapies S Iivanainen, J Ekstrom, H Virtanen, VV Kataja, JP Koivunen BMC Medical Informatics and Decision Making 21, 1-8, 2021 | 23 | 2021 |
| Treatment discontinuation and re-initiation of anti-PD-(L) 1 agents in metastatic cancers A Tikkanen, S Iivanainen, JP Koivunen Journal of Cancer Research and Clinical Oncology 146, 2153-2160, 2020 | 11 | 2020 |
| Tetracyclines increase the survival of NSCLC patients treated with EGFR TKIs: a retrospective nationwide registry study V Alanen, S Iivanainen, M Arffman, JP Koivunen ESMO open 5 (5), e000864, 2020 | 9 | 2020 |
| Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study S Kuusisalo, JP Koivunen, S Iivanainen Cancers 14 (9), 2276, 2022 | 5 | 2022 |
| Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial JH Rannikko, L Verlingue, M de Miguel, A Pasanen, D Robbrecht, ... Cell Reports Medicine 4 (12), 2023 | 4 | 2023 |
| Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to … AR Naqash, JD McCallen, E Mi, S Iivanainen, MA Marie, ... Journal for Immunotherapy of Cancer 11 (10), 2023 | 4 | 2023 |
| Promising clinical benefit rates in advanced cancers alongside potential biomarker correlation in a phase I/II trial investigating bexmarilimab, a novel macrophage-guided … P Bono, A Pasanen, L Verlingue, MJA de Jonge, MJ de Miguel, T Skytta, ... Journal of Clinical Oncology 40 (16_suppl), 2645-2645, 2022 | 4 | 2022 |
| Predicting onset and continuity of patient-reported symptoms in patients receiving immune checkpoint inhibitor (ICI) therapies using machine learning S Iivanainen, J Ekstrom, H Virtanen, J Koivunen Arch Clin Med Case Rep 4 (3), 344-351, 2020 | 4 | 2020 |
| Assessing the impact of digital patient monitoring on health outcomes and healthcare resource usage in addition to the feasibility of its combination with at-home treatment, in … S Iivanainen, AM Baird, B Balas, A Bustillos, AYC Sanchez, M Eicher, ... BMJ open 13 (4), e063242, 2023 | 3 | 2023 |
| Predicting objective response rate (ORR) in immune checkpoint inhibitor (ICI) therapies with machine learning (ML) by combining clinical and patient-reported data S Iivanainen, J Ekström, H Virtanen, VV Kataja, JP Koivunen Applied Sciences 12 (3), 1563, 2022 | 3 | 2022 |
| ePRO symptom follow-up of colorectal cancer patients receiving oxaliplatin-based adjuvant chemotherapy is feasible and enhances the quality of patient care: a prospective … S Iivanainen, R Ravichandra, A Jekunen, R Arokoski, S Mentu, L Lang, ... Journal of Cancer Research and Clinical Oncology 149 (10), 6875-6882, 2023 | 2 | 2023 |
| Purchase of prophylactic topical corticosteroids is associated with improved survival in NSCLCs treated with EGFR TKI: real-world cohort study V Alanen, S Iivanainen, M Arffman, JP Koivunen Acta Oncologica 60 (9), 1100-1105, 2021 | 2 | 2021 |
| Kohdennetut syövän hoidot: häviääkö syöpäkirurgia? JP Koivunen, S Iivanainen, P Karihtala Suomalainen lääkäriseura Duodecim, 2020 | 2 | 2020 |
| Impact of digital patient monitoring (DPM) on quality of clinical care of cancer immunotherapy (CIT)-treated patients (pts) with advanced/metastatic non-small cell lung cancer … OO Schmalz, C Jacob, J Ammann, B Liss, S Iivanainen, M Kammermann, ... Annals of Oncology 30, xi30-xi31, 2019 | 2 | 2019 |
